The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial

William V Bobo, Neil D. Woodward, Min Young Sim, Karuna Jayathilake, Herbert Y. Meltzer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder. Method: This was a 6-week, double-blind, placebo-controlled, fixed dose trial of armodafinil (150. mg/d) augmentation in patients with clinically stable schizophrenia or schizoaffective disorder. Cognition, psychopathology, alertness/wakefulness and adverse effects were assessed with standardized rating instruments. The primary endpoint was performance on measures of attention/vigilance. Results: Patients were randomly allocated to adjunctive armodafinil or placebo. There was a significant Drug × Time interaction effect for attention/vigilance, due to modest non-significant worsening in the armodafinil group and improvement in the armodafinil group [CPT-Pairs d', F(1,40) = 6.2, p = 0.017]. However, it became non-significant after correction for multiple comparisons. There were no differences between armodafinil and placebo in other cognitive domains or psychopathology measures. However, armodafinil was associated with significant improvement in the Scale for the Assessment of Negative Symptoms (SANS) anhedonia-asociality [F(1,41) = 4.1, p = 0.05]. Conclusions: There were no significant differences in neurocognitive measures between adjunctive armodafinil and placebo in this 6-week study. Armodafinil improved anhedonia-asociality, but not other negative symptom domains.

Original languageEnglish (US)
Pages (from-to)106-113
Number of pages8
JournalSchizophrenia Research
Volume130
Issue number1-3
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Psychopathology
Psychotic Disorders
Antipsychotic Agents
Schizophrenia
Placebos
Anhedonia
armodafinil
Affective Symptoms
Symptom Assessment
Wakefulness
Drug Interactions
Cognition
Safety

Keywords

  • Adjunctive treatment
  • Armodafinil
  • Depressive symptoms
  • Negative symptoms
  • Neurocognition
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder : A randomized, double-blind, placebo-controlled trial. / Bobo, William V; Woodward, Neil D.; Sim, Min Young; Jayathilake, Karuna; Meltzer, Herbert Y.

In: Schizophrenia Research, Vol. 130, No. 1-3, 08.2011, p. 106-113.

Research output: Contribution to journalArticle

@article{9dd73cae19134830b3cdc5a192e7ac6e,
title = "The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial",
abstract = "Background: The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder. Method: This was a 6-week, double-blind, placebo-controlled, fixed dose trial of armodafinil (150. mg/d) augmentation in patients with clinically stable schizophrenia or schizoaffective disorder. Cognition, psychopathology, alertness/wakefulness and adverse effects were assessed with standardized rating instruments. The primary endpoint was performance on measures of attention/vigilance. Results: Patients were randomly allocated to adjunctive armodafinil or placebo. There was a significant Drug × Time interaction effect for attention/vigilance, due to modest non-significant worsening in the armodafinil group and improvement in the armodafinil group [CPT-Pairs d', F(1,40) = 6.2, p = 0.017]. However, it became non-significant after correction for multiple comparisons. There were no differences between armodafinil and placebo in other cognitive domains or psychopathology measures. However, armodafinil was associated with significant improvement in the Scale for the Assessment of Negative Symptoms (SANS) anhedonia-asociality [F(1,41) = 4.1, p = 0.05]. Conclusions: There were no significant differences in neurocognitive measures between adjunctive armodafinil and placebo in this 6-week study. Armodafinil improved anhedonia-asociality, but not other negative symptom domains.",
keywords = "Adjunctive treatment, Armodafinil, Depressive symptoms, Negative symptoms, Neurocognition, Schizophrenia",
author = "Bobo, {William V} and Woodward, {Neil D.} and Sim, {Min Young} and Karuna Jayathilake and Meltzer, {Herbert Y.}",
year = "2011",
month = "8",
doi = "10.1016/j.schres.2011.05.015",
language = "English (US)",
volume = "130",
pages = "106--113",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder

T2 - A randomized, double-blind, placebo-controlled trial

AU - Bobo, William V

AU - Woodward, Neil D.

AU - Sim, Min Young

AU - Jayathilake, Karuna

AU - Meltzer, Herbert Y.

PY - 2011/8

Y1 - 2011/8

N2 - Background: The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder. Method: This was a 6-week, double-blind, placebo-controlled, fixed dose trial of armodafinil (150. mg/d) augmentation in patients with clinically stable schizophrenia or schizoaffective disorder. Cognition, psychopathology, alertness/wakefulness and adverse effects were assessed with standardized rating instruments. The primary endpoint was performance on measures of attention/vigilance. Results: Patients were randomly allocated to adjunctive armodafinil or placebo. There was a significant Drug × Time interaction effect for attention/vigilance, due to modest non-significant worsening in the armodafinil group and improvement in the armodafinil group [CPT-Pairs d', F(1,40) = 6.2, p = 0.017]. However, it became non-significant after correction for multiple comparisons. There were no differences between armodafinil and placebo in other cognitive domains or psychopathology measures. However, armodafinil was associated with significant improvement in the Scale for the Assessment of Negative Symptoms (SANS) anhedonia-asociality [F(1,41) = 4.1, p = 0.05]. Conclusions: There were no significant differences in neurocognitive measures between adjunctive armodafinil and placebo in this 6-week study. Armodafinil improved anhedonia-asociality, but not other negative symptom domains.

AB - Background: The efficacy, safety and tolerability of adjunctive armodafinil for cognitive performance, and negative and affective symptoms, were examined in 60 patients with schizophrenia or schizoaffective disorder. Method: This was a 6-week, double-blind, placebo-controlled, fixed dose trial of armodafinil (150. mg/d) augmentation in patients with clinically stable schizophrenia or schizoaffective disorder. Cognition, psychopathology, alertness/wakefulness and adverse effects were assessed with standardized rating instruments. The primary endpoint was performance on measures of attention/vigilance. Results: Patients were randomly allocated to adjunctive armodafinil or placebo. There was a significant Drug × Time interaction effect for attention/vigilance, due to modest non-significant worsening in the armodafinil group and improvement in the armodafinil group [CPT-Pairs d', F(1,40) = 6.2, p = 0.017]. However, it became non-significant after correction for multiple comparisons. There were no differences between armodafinil and placebo in other cognitive domains or psychopathology measures. However, armodafinil was associated with significant improvement in the Scale for the Assessment of Negative Symptoms (SANS) anhedonia-asociality [F(1,41) = 4.1, p = 0.05]. Conclusions: There were no significant differences in neurocognitive measures between adjunctive armodafinil and placebo in this 6-week study. Armodafinil improved anhedonia-asociality, but not other negative symptom domains.

KW - Adjunctive treatment

KW - Armodafinil

KW - Depressive symptoms

KW - Negative symptoms

KW - Neurocognition

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79960315525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960315525&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.05.015

DO - 10.1016/j.schres.2011.05.015

M3 - Article

C2 - 21641776

AN - SCOPUS:79960315525

VL - 130

SP - 106

EP - 113

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -